0.4196
Harvard Bioscience Inc stock is traded at $0.4196, with a volume of 747.42K.
It is down -5.05% in the last 24 hours and down -6.53% over the past month.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
See More
Previous Close:
$0.4419
Open:
$0.4447
24h Volume:
747.42K
Relative Volume:
0.94
Market Cap:
$18.69M
Revenue:
$106.79M
Net Income/Loss:
$-8.73M
P/E Ratio:
-2.098
EPS:
-0.2
Net Cash Flow:
$10.81M
1W Performance:
-6.55%
1M Performance:
-6.53%
6M Performance:
+8.79%
1Y Performance:
-81.91%
Harvard Bioscience Inc Stock (HBIO) Company Profile
Name
Harvard Bioscience Inc
Sector
Industry
Phone
(508) 893-8999
Address
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
HBIO
Harvard Bioscience Inc
|
0.4196 | 19.68M | 106.79M | -8.73M | 10.81M | -0.20 |
![]()
ISRG
Intuitive Surgical Inc
|
429.59 | 159.08B | 9.15B | 2.63B | 1.99B | 7.1661 |
![]()
BDX
Becton Dickinson Co
|
186.56 | 54.20B | 21.39B | 1.61B | 2.55B | 5.5609 |
![]()
RMD
Resmed Inc
|
272.00 | 40.55B | 5.15B | 1.40B | 1.65B | 9.5082 |
![]()
ALC
Alcon Inc
|
72.05 | 36.85B | 10.03B | 1.07B | 1.39B | 2.1549 |
![]()
WST
West Pharmaceutical Services Inc
|
261.77 | 18.95B | 2.96B | 487.70M | 344.00M | 6.6758 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Mar-10-23 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
Dec-09-20 | Initiated | Northland Capital | Outperform |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
Jul-08-19 | Downgrade | Janney | Buy → Neutral |
Jan-24-18 | Reiterated | Janney | Buy |
Jan-23-18 | Reiterated | The Benchmark Company | Buy |
Nov-17-16 | Initiated | Singular Research | Buy |
Jul-28-15 | Initiated | The Benchmark Company | Buy |
View All
Harvard Bioscience Inc Stock (HBIO) Latest News
Forecasting Harvard Bioscience Inc. price range with options data2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
Using economic indicators to assess Harvard Bioscience Inc. potential2025 Top Gainers & Reliable Price Breakout Signals - newser.com
Will Harvard Bioscience Inc. stock reach Wall Street targetsTrade Signal Summary & Safe Entry Momentum Stock Tips - newser.com
Harvard Bioscience Inc. stock chart pattern explainedRisk Management & Real-Time Market Trend Scan - newser.com
What analysts say about Harvard Bioscience Inc stockUtilities Sector Analysis & Double Or Triple Returns - earlytimes.in
What drives Harvard Bioscience Inc stock priceAnalyst Downgrades & Stocks With 200% Upside Potential - earlytimes.in
Is Harvard Bioscience Inc. (HBI) stock at risk of policy regulationJuly 2025 Analyst Calls & Free Long-Term Investment Growth Plans - newser.com
What’s the recovery path for long term holders of Harvard Bioscience Inc.2025 Short Interest & Fast Gaining Stock Reports - newser.com
Is Harvard Bioscience Inc. (HBI) stock supported by free cash flowJuly 2025 Macro Moves & Free Technical Pattern Based Buy Signals - newser.com
How to integrate Harvard Bioscience Inc. into portfolio analysis toolsEarnings Summary Report & Accurate Entry/Exit Alerts - newser.com
Harvard Bioscience appoints interim CFO amid market challenges By Investing.com - Investing.com Nigeria
Harvard Bioscience gets another 180 days to try to stay on the Nasdaq - Worcester Business Journal
Harvard Bioscience granted 180 days for complianceSEC filing - MarketScreener
Harvard Bioscience receives extension to regain Nasdaq bid price compliance - Investing.com
Harvard Bioscience Granted Nasdaq Compliance Extension - TipRanks
Applying Elliott Wave Theory to Harvard Bioscience Inc.2025 Technical Overview & Smart Investment Allocation Tips - newser.com
Is it too late to sell Harvard Bioscience Inc.Portfolio Growth Summary & Capital Efficiency Focused Ideas - newser.com
Is Harvard Bioscience Inc. (HBI) stock worth holding before Fed meetingJuly 2025 Volume & Daily Stock Trend Watchlist - newser.com
What machine learning models say about Harvard Bioscience Inc.Quarterly Growth Report & Capital Efficient Trade Techniques - newser.com
Why Harvard Bioscience Inc. (HBI) stock is a strong buy callJuly 2025 Technicals & Verified Swing Trading Watchlists - newser.com
What high frequency data says about Harvard Bioscience Inc.2025 Valuation Update & Long-Term Growth Stock Strategies - newser.com
Harvard Bioscience Inc Stock (HBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):